From: Association of MTHFR gene polymorphisms with breast cancer survival
Age at diagnosis (mean ± SD; n = 248) | 55.0 ± 13.9 |
Body mass index (mean ± SD; n = 248) | 29.1 ± 8.0 |
N (%) | |
Race/Ethnicity | |
African-American | 143 (58) |
Caucasian | 105 (42) |
Menopausal status at diagnosis | |
Pre-menopausal | 64 (31) |
Post-menopausal | 141 (69) |
Alcohol consumption | |
No | 93 (41) |
Yes | 133 (59) |
Survival | |
Alive | 189 (76) |
Deceased2 | 59 (24) |
Tumor histology | |
Ductal | 189 (76) |
Lobular | 34 (14) |
Others | 25 (10) |
Node status | |
Negative | 144 (63) |
Positive | 84 (37) |
Stage at diagnosis (TNM) | |
≤ Stage I | 66 (29) |
Stage II | 118 (52) |
≥ Stage III | 44 (19) |
Chemotherapy | |
No | 99 (43) |
Yes3 | 132 (57) |
Neoadjuvant therapy | |
No | 178 (77) |
Yes | 53 (23) |
Estrogen receptor-α | |
Negative | 102 (41) |
Positive | 145 (59) |
HER2/neu | |
Low to weak | 154 (62) |
Moderate to strong | 93 (38) |